Aim-We report a magneto-fluorescent theranostic nanocomplex targeted to neutrophil gelatinase associated lipocalin (NGAL) for imaging and therapy of pancreatic cancer.
Introduction
Pancreatic cancer is the fourth leading cause of cancer-induced mortality in the United States, accounting for 36,800 estimated fatalities in 2010 [1] . Its dismal five-year survival rate of 5% is attributed primarily to rapid metastasis and to a lack of reliable tumor markers for early diagnosis. Among patients without metastatic disease, less than 20% are surgically resectable, the only potentially curative treatment, which still confers only a 15-25% rate of 5-year overall survival [2] . Other patients are frequently treated with chemo-radiation therapy with 5-year overall survival rates of 5-10% [3, 4] . Current therapies, alone or in combination, have done little to improve the grim outlook, since pancreatic cancer has low response to chemotherapy, and develops resistance to gemcitabine, the standard first-line chemotherapeutic agent for advanced stage disease [5] . The development of a method for detection and therapy of early stage pancreatic cancer, immune to drug resistance, would be immensely helpful for improving the chance of survival.
Cancer nanotechnology developments in the area of theranostic probes (combined diagnosis and therapy) provide an attractive avenue for detecting and treating pancreatic cancer [6] [7] [8] [9] [10] . Recently we demonstrated the theranostic capabilities of multifunctional magnetofluorescent silica core-gold nanoshells for diagnosis and photothermal therapy of cancer [11] [12] [13] . These agents are comprised of a silica core with a thin gold layer whose thickness can be varied to tune the plasmon resonance wavelength of the nanoparticle into the NIR wavelength region, where light penetration in tissue is maximal. In addition to photothermal therapy, these complexes enhance the fluorescence of the only FDA cleared NIR dye Indocyanine Green (ICG) by up to 50X, resulting in a biocompatible, yet stable and bright NIR fluorescence with imaging performance comparable to the semiconductor quantum dots. As the outcome of pancreatic cancer surgery strongly depends on the margin status, deployment of magneto-fluorescent theranostic probes for image guided surgery/thermal therapy can favorably impact the care of pancreatic cancer patients.
For maximal impact on pancreatic cancer, the emerging cancer theranostics should be targeted to early stage malignancies. However, there is a scarcity of early stage tumor biomarkers for pancreatic cancer along with the lack of clinical validation [14] [15] [16] [17] [18] . Recently, neutrophil gelatinase-associated lipocalin (NGAL) has been detected in pancreatic cancer tissue and it has been clinically investigated as a marker for early diagnosis of pancreatic intraepithelial neaoplasia [19, 20] . NGAL has been reported to be up-regulated up to 27 times in pancreatic cancer cells [19] . NGAL expression is also up-regulated in multiple human cancers including breast, colorectal, ovarian, thyroid carcinomas, prostate and bladder [21] [22] [23] [24] [25] [26] [27] , implying that NGAL may have a critical role in solid tumor formation. In particular, strong NGAL over-expression has been observed in early stage pancreatic cancer lesions, suggesting that it is a marker for early dysplasia in pancreas and an attractive target for cancer theranostic nanoprobes.
We report that silica-gold-iron-oxide magneto-fluorescent TGNS complexes can be used for combined image contrast and photothermal therapy of pancreatic cancer overexpressing NGAL. The agent was comprised of a silica core-gold shell nanoshell with an additional silica epi-layer encapsulating approved NIR (ICG) and MR (iron oxide) contrast agents. The agents were targeted to NGAL-overexpressing cells via antibodies conjugated to the external surface of the complex. Nanocomplex dimensions were tuned to provide a plasmon resonance at ~808 nm, coinciding with the emission maximum of the fluorescent dye ICG, and thus enhancing its quantum yield by ~50X. The resulting probe acted as an NIR imaging agent when illuminated with 785 nm light, and as a photothermal therapy agent when illuminated with 808 nm light. We identified the efficacy of TGNS for image contrast and therapy of pancreatic cancer in vitro and in vivo on disease models created with AsPC-1, a human pancreatic adenocarcinoma cell line known to overexpress NGAL. In vitro MRI and fluorescence optical imaging (FOI) verified the enhanced specific binding of NGAL targeted TGNS to AsPC-1 cells. We also report the lack of cytotoxicity of these constructions and nearly 100% efficiency in ablation of the cancer cells upon exposure to NIR radiation at 808 nm. In vivo MRI and FOI imaging studies on nude mice with AsPC-1 xenografts were conducted to demonstrate the favorable biodistribution of NGAL targeted TGNS to tumors following systemic delivery.
Materials and Methods

In vitro Fluorescence Optical Imaging
The purpose of in vitro imaging was to validate the targeting efficacy and specificity of antiNGAL-TGNS for NGAL expressing pancreatic cancer cells by standard immunohistochemistry techniques. AsPC-1 (human, pancreas, adenocarcinoma, derived from metastatic ascites) cells were grown in RPMI 1640 medium with 2.05 mM LGlutamine (HyClone), 1% Antibiotic-Antimycotic and 10% FBS. Cells were incubated at 37°C in a 5% CO 2 environment and detached from culture with 0.05% trypsin /0.53mM EDTA, then resuspended in media for passaging to wells. 3×10 5 cells of ASPC-1 were plated in each well of 4 well plates respectively, and allowed to incubate. Subsequently, cells were washed with 1×PBS twice and fixed with PFA (3.7% paraformaldehyde in PBS). Cells were then permeabilized with 0.2 % triton, following which they were washed twice with PBS. 10% NGS solution was added to each well plate and incubated for 15 min. The cells were divided into three groups: The NGAL group (AsPC-1 incubated with antiNGALconjugated TGNS with concentration 2×10 9 particles/mL 2 h at 4°C) was the experimental group while the blocked group (AsPC-1 incubated with antiNGAL-conjugated TGNS after blocking NGAL with antiNGAL, 20 µg/mL, 1 h at 4°C then washed three times with PBS 5min) and the unconjugated TGNS group (AsPC-1 cells incubated with unconjugated TGNS for 2 h at 4°C) were the controls. After 2 h, the cells were washed with PBS to remove unbound nanocomplexes, after which the secondary antibody, Goat Anti-Rabbit IgG-Alexa Fluor 488 (Invitrogen) was added to the wells and incubated for 1 h at 4°C. The cells were again washed with PBS while protected from light for excess secondary antibody removal. The cell plates were then mounted on slides with mounting media containing DAPI (Invitrogen) and prepared for fluorescence imaging. To acquire the fluorescence images, we used a Leica fluorescence microscope (DM6000 B; Leica Microsystems GmbH) with a 100 W xenon lamp and specific filters. The images were obtained using cutoff filters with appropriate excitation/emission wavelengths (laser excitation/emission wavelengths 360/470 nm (DAPI), 480/530 nm (Alexa Fluor 488), and 720/820 nm (ICG).
In vitro MR Imaging
1×10 6 AsPC-1 cells were plated in each well of 60×15 mm style cell culture dishes and allowed to incubate with the TGNS as described in the previous section. After 2 h of incubation with the nanocomplexes, the cells were washed with PBS, followed by scraping the cells from the bottom of the petri dish, dispersed in 500 µL PBS, and centrifuged at 1100 rpm for 5 min. The supernatant was then removed, leaving ~100 µL cells containing antiNGAL-conjugated TGNS and unconjugated TGNS in the Eppendorf tubes, respectively. 500 µL of 0.5% agarose gel was added to each tube and the samples were left at 4°C for 10 min to allow the agarose to solidify. The tubes with the nanocomplexes suspended within the gel containing the solidified agarose gel with AsPC-1 cells were directly utilized for MR Imaging. MRI experiments were performed on a Bruker Avance Biospec, 9.4 T spectrometer, 21 cm bore horizontal imaging system (Bruker Biospin, Billerica, MA) with a 35 mm volume resonator. In vitro imaging of cells suspended in agarose was performed using a 3D RARE (rapid acquisition with relaxation enhancement) sequence with a repetition time (TR) of 2000 ms, an echo time (TE) of 20 ms (TR/TE equal to 2000/20 ms) with a RARE factor of 8 leading to an effective TE of 60 ms. FOV was 25.6×25.6×12.8 mm with an acquisition matrix of 128×128×64 yielding an isotropic 200 µm resolution. Maximum intensity projections were created from the 3D MRI data using a threshold segmentation approach in MATLAB® (2008a, The Mathworks, Natick, MA). The threshold was set at the average minus twice the standard deviation of the sample. Pixels under this value were considered to be hypointense and labeled as black in the image. The surrounding normotense agarose was labeled as a transparent light green. Each hypointense pixel contains a cluster of labeled cells, since the scan resolution was not sufficient to identify individual cells.
In vitro Photothermal Therapy and Cytotoxicity Studies
AsPC-1 cells were grown in a 4 well plate and divided into three groups, as described earlier. 5×10 5 cells were incubated at 37 °C with nanocomplexes (2×10 9 particles/mL) for 2 h and then washed with PBS. Photothermal ablation was performed using an NIR laser diode at 808 nm (L808P200, Thorlabs Inc.) for 10 min at a power density of 5.81 W/cm 2 and a spot size of ~0.8mm diameter. After irradiation, cells were rinsed gently with PBS and incubated at 37 °C with media for 4 h. Cell viability was assessed using Calcein to stain live cells and propidium iodide (PI) to stain dead cells. For cytotoxicity studies, cells were incubated at 37 °C with antiNGAL-conjugated TGNS, free antiNGAL followed by antiNGAL-conjugated TGNS, and unconjugated TGNS, these cells were not illuminated with the NIR laser. After incubating the cells with Calcein/PI mixture for 30 min at 37°C, a cover slip was mounted and the cells were imaged. The images were obtained using excitation/emission wavelengths 480/530 nm (Calcein), 520/620 nm (PI).
The AsPC-1 xenograft model-The protocol for xenograft tumor creation and nude mice imaging was approved by the Institutional Animal Care and Use Committee (IACUC) of Baylor College of Medicine.
Athymic Nude-Foxn1nu female mice (4-6wk of age, 20±3g, Harlan) were injected s.c. on the right flank with 4×10 6 cells per mouse, AsPC-1 cells suspended in 0.2ml serum-free medium. After 14 days, tumors grew to about 8-12mm in diameter. Intravenous administration of nanocomplexes in mice was conducted in two stages. In the first stage, the specificity of antiNGAL-TGNS for the AsPC-1 xenografted tumors was determined. Mice were randomized into an experimental group (n=7) and a control group (n=6). Mice treated with antiNGAL-conjugated TGNS comprised the experimental group. As a control, mice were treated with free antiNGAL antibody (250 µg in 200 µL of saline injected through the tail vein) to block NGAL 4 hours prior to injecting antiNGAL-conjugated TGNS. In both cases, nanocomplexes were administered via 200 µL tail vein injections with concentration of 5×10 9 particles/mL. In a second set of experiments the time dependent NIR/MR imaging was compared between antiNGAL-conjugated TGNS and PEGylated TGNS to evaluate the contrast advantages of targeting over passive accumulation in tumor by enhanced permeability and retention (EPR) affect due to PEGylation. Mice were randomized into an antiNGAL-TGNS treated group (n=6) and PEGylated-TGNS treated group (n=6).
Fluorescence Imaging Method
Mice were placed in a clear plastic chamber and isoflurane delivered in concentrations of 1-3% in oxygen (up to 5% for initial induction). To maintain body heat of the mice during anesthesia, we utilized a heating pad and temperature controller (FHC Bowdoin, ME, USA). Whole body fluorescence images at 0.5 h, 2 h, 4 h, 24 h, 48 h, and 72 h post-injection were acquired using a homebuilt NIR imaging system consisting of an image-intensified cooled CCD camera (Princeton Instruments) outfitted with a 28 mm Nikkor (Nikon) lens. Image acquisition was controlled by customised MATLAB routines (The MathWorks, Inc.) from an off-the-shelf personal computer (Dell Optiplex 760). Excitation light was generated with a 100 mW near infrared (NIR) laser diode at 785 nm (Thorlabs, Inc.) and diffused with a planoconvex lens and a light shaping diffuser (both Thorlabs, Inc.). For capturing excitation light images we used a neutral density filter with optical density (OD) 3 (Andover Corporation). A fluorescence band pass filter at (830 ± 20) nm (Andover Corporation) in combination with a holographic notch filter (OD 6) at 785 nm (Kaiser Optical Systems, Inc.) was employed for collecting fluorescence emission light while rejecting excitation leakage, as suggested by Hwang et. al [28] . From the images, regions of interests (ROIs) were manually selected around the tumor and non-tumor sites. The ratios of the fluorescence intensities from these ROIs were then calculated.
In vivo MRI Methodology
Animals were anesthetized with gaseous isoflurane at 1-3% in oxygen, then placed into a mouse holder within the magnet. During imaging, the animal body temperature was maintained at 37°C, continually monitored with a rectal probe using an animal warmed-air heating system (SA Instruments, Stony Brook, NY). Imaging was performed with a multislice RARE (rapid acquisition with relaxation enhancement) sequence with a TR/TE equal to 2805/20 ms with a RARE factor of 6 leading to an effective TE of 60 ms. The imaging sequence included a 5 ms fat suppression pulse. FOV was 30×30 mm with 20 slices at 1 mm thickness. The acquisition matrix of 256×256 yielded an in-plane isotropic 117 µm resolution. The transverse relaxation time T2 weighting sufficient for detection of superparamagnetic iron oxide. Qualitative criteria for the diagnosis of tumor were based on the identification of single or multiple focal zones of increased or decreased signal tumor intensity. Signal tumor intensity measurements were scaled to image noise, and tumor intensity compared before and after injection of nanocomplexes.
Results
TGNS characterization
The TGNS complexes were chemically synthesized by a stepwise multi-layered deposition process as described in supplementary information. The correct assembly and functionality of each layer was characterized. A schematic illustration of the assembly process of antibody (anti-NGAL) conjugation to TGNS is depicted in Fig. 1A . The binding of Iron Oxide to gold nanoshells and localization inside silica layer was confirmed by TEM (supplementary information Fig. S1 ). Fluorescence emission from the ICG doped inside the silica is provided in Fig. S2B . The size of the TGNS is ~180 nm according to TEM measurements (Fig. 1B) . FTIR spectra of the streptavidin-conjugated TGNS and controls (bare-TGNS and streptavidin) were obtained to confirm the binding of streptavidin to the bare-TGNS (Fig. 1C) . The peak at 3303 cm −1 corresponds to the N-H stretching mode present in streptavidin and in the conjugated TGNS but absent in bare-TGNS. In addition, the peaks at 1521 cm −1 (N-H bending mode) and 1635 cm −1 (C=O stretching mode) increase in intensity after streptavidin conjugation to the bare-TGNS. Quantification of the number of antibodies on anti-NGAL conjugated TGNS by ELISA is significantly higher than that of the control (bare-TGNS), as shown in Fig. 1D . These nanocomplex characteristics support the expected conjugation of antiNGAL-biotin to TGNS using the streptavidin-biotin interaction. Further characterization of TGNS bioconjugation is provided in supplementary information (Fig. S2 ) including optical properties, zeta potential and hydrodynamic diameter.
AntiNGAL-conjugated TGNS bind pancreatic cancer cells in vitro to facilitate photothermal therapy
The efficacy of antiNGAL TGNS for binding to NGAL expressed in pancreatic cancer cells was studied via FOI and T2-weighted MR imaging of cultured AsPC-1 cells. Fluorescence microscopy results are illustrated in Fig. 2A . The antiNGAL-conjugated TGNS preferentially bound to cells over-expressing NGAL vs the blocked group, and the unconjugated-TGNS treated group. 2-D MR images showed that the number of hypointense pixels of AsPC-1 cells labeled with antiNGAL-conjugated TGNS (Fig. 2B ) was higher than that observed with the blocked group and with the unconjugated-TGNS. The accompanying thresholded 3-D MR images gave a visual representation of the distribution of nanocomplex-conjugated cells. The brown spots represent the nanocomplex-labeled cells and the surrounding green regions represent the agarose medium. As the imaging studies were performed on fixed cells, these experiments only validated the specific binding of antiNGAL TGNS to immobilized NGAL expressed on AsPC-1 cells. In vitro NIR photothermal therapy/cytotoxicity experiments were conducted with live cells and results showed that almost complete cell death in the laser treated region was observed for AsPC-1 cells labeled with antiNGAL-conjugated TGNS (Fig. 2C) . Such an effect was not observed for the blocked group, nor for the unconjugated TGNS treated group, which further validated the specific binding of antiNGAL TGNS, this time in live cells. In the cytotoxictiy studies, the NIR laser was not applied and cell death was not significantly observed in the experimental group, and neither in the two control groups. This verifies that the gold nanoshell based cancer therapy observed was of an externally controlled nature (induced by incident NIR laser light).
AntiNGAL-conjugated TGNS enhances accumulation in tumor possibly by interacting with NGAL
To study the specificity of antiNGAL-conjugated TGNS targeting of pancreatic tumors and the impact of molecular targeting on biodistribution of ~180 nm nanocomplexes, we used NIR-FOI for tracking the fluorescence contrast evolution in the two groups of mice with NGAL overexpressing xenografts. The results are illustrated in Fig.3 , for a representative animal from each group. Group 1 was comprised of mice treated with antiNGAL-conjugated TGNS (Fig. 3A, bottom row) , and the control group comprised of mice treated with NGALblocked by prior free antiNGAL injection (Fig. 3A, top row) . Mice were imaged at 0.5 h, 2 h, 4 h, 24 h, 48 h and 72 h post-injection. The images are depicted in a pseudocolor scale with intensities normalized with respect to the maximal value for the experimental group mice, which demonstrated the maximum fluorescence in tumors among the two groups. Substantial differences in fluorescence contrast variation within the mice bodies, especially between the targeted and NGAL blocked cases are clear. Qualitatively, the fluorescence intensity in the tumor was lower for the blocked mice. To account for variations across animals and imaging conditions, Tumor-to-Background Ratio (TBR) were computed by selected tumor and normal ROIs from each image. TBR was plotted vs time for the two groups in Fig. 3B . The TBR variation is significant between the two groups (p=0.0177), while the variation across time points is not significant (p=0.0779), which is expected, since the TBR is more or less constant from 24 to 72 hours. The results suggest that targeting NGAL overexpression increases the NIR fluorescence contrast in tumors by 60-70% at 24 hours after injection and is indicative of enhanced accumulation in tumors for NGAL targeted particles.
While NIR images are strongly surface weighted due to multiple scattering and attenuation related losses from deep tissue signal, the iron oxide component of the nanocomplexes enables the observation of 3D spatial variations via T2-weighted MR imaging. Each of the mice was imaged in a small animal MR scanner after NIR imaging. Iron oxide is a negative contrast agent, where the image intensity is lowered in areas of nanocomplex accumulation. A representative image of the tumor central cross section for the mice from the NGAL blocked group, and the experiment group at 24 hours post-injection is depicted in Fig. 4A and 4B, respectively. A water phantom was placed along with the mice to allow normalization to account for unintentional variations in scanning conditions. The experimental group image demonstrates greater lowering of T2 intensity of the tumor relative to the water control (T2 Intensity reduced to 41.41% of water control intensity) compared to the NGAL blocked group (T2 Intensity reduced to 82.52% of water control intensity). For quantitative comparison of nanocomplex biodistribution and to account for statistical variation across animals and imaging conditions, the tumor ROIs were manually segmented from each reconstructed slice, and the tumor-to-body T2 intensity was determined, which was then averaged over all slices. The obtained tumor-to-body ratio was averaged over mice in each group and plotted in Fig. 4C . It is clear that the accumulation of nanocomplexes in tumors is increased by targeting NGAL, and the overall trend is similar to that obtained in NIR fluorescence images, with the difference that in MR the cross-sections of the tumors have been analyzed and there is no surface weighing as in NIR imaging. The relative contrast between T2 intensity ratios is approximately 30% at 24 hours postinjection, compared to 60-70% in case of NIR, which is expected as NIR imaging is more sensitive.
To analyze the biodistribution of nanocomplexes in different organs and infer information about their bio-elimination, the animals were sacrificed at 72 hours post-injection and the resected organs were imaged with the NIR imaging system under conditions identical to in vivo imaging, as illustrated in Fig.5 (A, B) . The highest fluorescence intensities were observed in tumors of the experimental group compared to the NGAL blocked control group. The luminous intensity on the unit surface area of each tissue suggested that the tumors have a higher nanocomplex uptake compared to other tissue. To quantitatively determine the biodistribution, the Au content in each organ was measured by ICP-MS (Fig.  5C) . The results corresponded well to the fluorescence intensities reported in Fig. 5B , with the exception of liver and spleen, which have high NIR absorption and as a result the fluorescence from the accumulated nanocomplexes is internally absorbed and not registered with the imaging system. The ICP-MS results demonstrated the specificity of antiNGAL conjugated nanocomplexes for targeting NGAL overexpressing pancreatic cancer cells in vivo. As expected, tissues of the overexpressing NGAL xenografts have higher nanocomplex accumulation than the blocked group. Consistently with this observation strong light scattering in dark-field microscopy corresponding to gold nanoshells were localized in tumor tissue with the targeted TGNS, compared to the blocked NGAL controls (Fig. 5D) . Immunohistochemical staining of tumor sections verified the strong NGAL expression, and vascularized nature of xenografted AsPC-1 tumors. (supplementary information Fig. S3 ) Mean tumor accumulation of nanocomplexes for antiNGAL-TGNS injected mice was twice as high compared to animals with prior injections of free antibody. The statistical variation across experimental groups (p=0.0045) was significant for ICP-MS quantification of the gold level in tumors. The measured Au levels in lungs and heart may be due to the residual blood left behind in these highly perfused tissues. Both fluorescence and ICP-MS measurements show low Au concentration in brain, indicating that the nanocomplexes have low permeation through the blood-brain-barrier, probably due to their size.
Performance of antiNGAL-conjugated TGNS versus PEG-TGNS on imaging
The second set of in vivo experiments investigated the performance of long circulating PEG-TGNS agents vs antiNGAL-TGNS agents, which were also PEGylated following antiNGAL conjugation. Passive accumulation of nanoparticles in tumors using PEG-TGNS was compared against the active NGAL targeting effect of the antiNGAL-TGNS (Fig. 6 ). The TBR with the antiGNAL-TGNS is significantly higher than the PEG-TGNS across all imaging time points (Fig. 6A, 6B) , suggesting there is an effect on active NGAL targeting using anti-NGAL. In addition, the antiNGAL-conjugated TGNS result in a greater lowering of T2 intensity on the pancreatic tumor compared to the only the PEG conjugated TGNS (Fig. 6C, 6D) . The temporal behavior of T2 contrast in Fig. 6D is different from Fig 4C for time points after 24 hrs. While strong contrast differences between PEG-TGNS and antiNGAL-TGNS are clear at early timepoints, compared to Fig. 4C , the tumors from experiment group lost contrast after 24 hours. This may be because of fluctuations in MR measurements arising from differences in positioning of mice from day to day, the possibly lower iron-oxide loading of nanoparticles in this batch resulting in reduced sensitivity, or lower uptake in this batch of tumors.
Discussion
The nanocomplex presented here integrates targeting, diagnosis, and photothermal therapy all within the same nanostructure. The complimentary features of high sensitivity NIR molecular imaging and high resolution 3D MR imaging are both enhanced by integration into the theranostic nanostructure. The immunotargeting allowed the antiNGAL-conjugated TGNS to specifically attach to pancreatic cancer cells over-expressing NGAL in amounts up to four times more than in the case of blocked NGAL, or unconjugated TGNS, under in vitro settings. Moreover, photothermal therapy in vitro was shown to effectively ablate the cancer cells only when the nanocompex was antiNGAL-conjugated. Both unconjugated and antiNGAL-conjugated nanocomplexes were not toxic to the cells in the absence of 808 nm NIR illumination, confirming the externally modulated nature of nanocomplex-mediated photothermal therapy. Recently the toxicity of gold nanoshells has been evaluated extensively including cytotoxicity, pyrogenecity, genotoxicity, hemolysis, systemic toxicity and intracutaneous reactivity without any indication of toxicity in any of the studies [29] .
Similar trends for NGAL targeting were observed in vivo by NIR-FOI and MRI. Imaging experiments validated the specific binding of antiNGAL-TGNS to tumors as a consistent higher contrast both in NIR and MR imaging was observed for mice injected with antiNGAL-TGNS compared to when mice were pre-injected with free antiNGAL. Both techniques complemented each other, as FOI showed higher sensitivity than MRI. However, MRI allowed imaging of tumor cross-sections with high 3D spatial resolution. The nanoparticle biodistribution studied by FOI in each organ and ICP-MS also confirmed quantitatively that nanoparticle uptake within the tumor is enhanced by NGAL targeting. ICP-MS also revealed that the nanoparticles accumulate in liver and spleen in substantial amounts which was anticipated since particles > 10 nm are scavenged by the macrophages of the reticuloendothelial system and accumulate in liver and spleen [30, 31] . The enhancement in imaging contrast was again observed when antiNGAL-TGNS were compared with PEG-TGNS. It should be noted that antiNGAL-TGNS were also PEGylated, However, PEG-TGNS agents in spite of having a longer circulation time, showed inferior contrast in tumors especially at the early time points, possibly because of their extended circulation half life. The tumor to body ratio was seen to exceed unity for PEG-TGNS (Fig.  6D ) and antiNGAL-TGNS (Fig. 4C) when prior injections of free antibody was performed. This indicated higher amounts of TGNS in circulation compared to accumulation in tumors.
Even as our targeting strategy against NGAL on the pancreatic cancer cell line AsPC-1 was effective in the mouse xenograft model, numerous challenges remain for clinical translation. NGAL is typically stored in neutrophil granules, and is present systemically, which can adversely impact bio-distribution in humans. The rationale for using NGAL for targeting pancreatic cancer is three fold: (i) There is a scarcity of biomarkers for early stage pancreatic cancer, when the disease has the best response to treatment, (ii) NGAL is significantly (27 fold) overexpressed in pancreatic cancer, compared to normal pancreatic tissue and acute pancreatitis, and (iii) nanocomplexes targeting NGAL are inherently non-cytotoxic and can be locally activated only by application of NIR light, with NIR/MR imaging guidance.
Many other biological events have been discovered to be associated with NGAL, such as inhibition of bacterial iron uptake, renal injury, and mediation of inflammatory activity [32] [33] [34] [35] . Moreover, NGAL is associated with human atherosclerotic lesions by forming a NGAL-MMP-9 complex which prolongs matrix metalloproteinase-9 activity [36] [37] [38] and thus recently NGAL targeting with nanoparticles has been demonstrated for MRI studies of the atherosclerotic plaque [39] . Since, we employed antihuman NGAL targeted TGNS in a mouse model, the contrast in xenografted human tumors was maximized, however, in the artherosclerotic plaque imaging study reported in reference [38] , antimouse NGAL antibody (vs antihuman NGAL in the present study) was employed for targeting magnetic micelles to vascular disease sites in a genetically engineered mouse, and irrespective of systemically distributed mouse NGAL, MR image contrast in plaque with NGAL overexpression was achieved. The fact that NGAL is up-regulated in certain injury and inflammatory states can potentially reduce the effectiveness of proposed agents and lead to off-target effects, and the discrimination of cancer can be difficult in chronic pancreatitis patients. However, it has been reported that in the context of Pancreatic Cancer, NGAL levels progressively increase with disease progression, but decrease in advanced stages of the disease (stage-4) [19] . Hence the proposed probe will be suited for early stage interventions, when chemo-radiation therapy induced injury to internal organs is not present.
In summary, antiNGAL-conjugated TGNS are promising candidates for diagnosis and treatment of pancreatic cancer, especially in early stages when NGAL over-expression is significant. Fully exploited, the proposed theranostic nanocomplexes can contribute to lowering the morbidity and mortality associated with pancreatic cancer.
Future Perspectives
The results presented in this study pave the way towards photothermal therapy in an in vivo tumor graft under FOI/MRI guidance. In this imaging focused study, the injected TGNS concentration was limited to ~5e9 particles/ml, which is more than two orders of magnitude lower than concentration used in prior studies on gold nanoparticle mediated photothermal therapy [9] hence prospects of successful image guided photothermal therapy are bright. However, a major challenge for targeting pancreatic cancer with nanoparticles irrespective of the targeting mechanism is circumventing the intense stroma, and desmoplastic reactions around the pancreatic cancer lesions [40] , which are not replicated in the subcutaneous xenograft tumor model. The current NGAL targeted TGNS embodiments at >150nm diameter, while successful in generating high NIR and MR contrast, may not have optimal penetration in orthotopic tumors. Overcoming tumor transport barriers is a multifaceted undertaking with nanoparticle size expected to have a significant role. Current research efforts are underway to reproduce NIR plasmon resonance, NIR fluorescence enhancement, and MR contrast in 50-100nm particle sizes, by utilizing alternate geometries including nanosphere inside a nanoshell (nanomatryoshka), or hollow gold nanoshells [41, 42] . A key technology for multimodal contrast enabled photothermal therapeutic agents is the deposition of reproducible and tunable width silica layers on gold surfaces, which was demonstrated in this paper for silica core gold nanoshells, but can be adapted for gold nanoparticles in other size regimes.
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Executive summary
Introduction
• Neutrophil gelatinase associated lipocalin (NGAL) is a promising marker for early diagnosis of pancreatic intraepithelial neaoplasia.
• Theranostic gold nanoshells (TGNS) allow MRI/fluorescence optical imaging and photothermal therapy.
• Antibody conjugated TGNS for targeting NGAL overexpressing Pancreatic Cancer was investigated.
TGNS characterization
• TGNS are composed of plasmonic gold nanoshells with a silica epi-layer doped with iron oxide/indocyanine green that enable photothermal therapy with enhanced MRI/NIR-fluorescence imaging of cancer with FDA cleared components.
AntiNGAL-conjugated TGNS bind pancreatic cancer cells in vitro to facilitate photothermal therapy
• TGNS nanocomplexes are nontoxic to cancer cells in the absence of lasermediated activation of photothermal heating.
• AntiNGAL-conjugated TGNS specifically bind to AsPC-1 human pancreatic cancer cells and thus mediate targeted photothermal therapy and MRI/NIRfluorescence imaging in vitro.
AntiNGAL-conjugated TGNS enhances accumulation in tumor possibly by interacting with NGAL
• AntiNGAL-conjugated TGNS enable specific targeting of pancreatic cancer xenografts (AsPC-1 cell line) in mice following systemic delivery.
• Circulation of molecularly targeted TGNS has been tracked in vivo using MRI and NIR-fluorescence imaging.
• AntiNGAL-conjugated TGNS enable imaging of pancreatic tumors with higher contrast with both NIR and MR imaging, and result in higher tumor deposition of gold than the non-conjugated TGNS.
Conclusion
• TGNS enabled molecularly targeted imaging and photothermal therapy of pancreatic cancer cells with expression of early disease marker NGAL.
• TGNS were successful for dual modality in vivo NIR-MR imaging of NGAL overexpressing Pancreatic Cancer in a subcutaneous tumor model. 
